A Phase 2 interventional study of RGT001-075 and Placebo in Obesity, sponsored by Regor Pharmaceuticals Inc.. Completed at 10 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-07.
Sponsored by Regor Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study was to evaluate the safety and tolerability of RGT001-075 in healthy participants with obesity
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 73 is close to the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Regor Pharmaceuticals Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive once daily dose of study drug for a total of 12 weeks
Drug: RGT001-075
Patients will receive once daily dose of matching placebo for a total of 12 weeks
Drug: Placebo
Administered orally
Administered orally
Number of participants with Treatment-emergent Adverse Event(AE) by severity/Serious Adverse Event (SAE), with Clinical Laboratory Abnormalities, Clinically Significant Change From Baseline in Vital Signs and Abnormal Electrocardiogram(ECG) readings
Time frame: 14 weeks
Percent change in body weight
Percent change in body weight from baseline at Week 12
Time frame: 12 weeks
Change in body weight in kilogram
Change in body weight from baseline at Week 12
Time frame: 12 weeks
Percentage of participants who achieve ≥5% and ≥10% body weight reduction
Percentage of participants who achieve ≥5% and ≥10% body weight reduction at Week 12
Time frame: 12 weeks
Change in Body mass index (BMI) in kg/m^2
Change in BMI from baseline at Week 12
Time frame: 12 weeks
Change in waist circumference in centimetre
Change in waist circumference from baseline at Week 12 .
Time frame: 12 weeks
RGT001-075 pharmacokinetics (PK): Area under the curve up to the last measured concentration(AUC0-last)
Analysis of AUC0-last
Time frame: 12 weeks
RGT001-075 pharmacokinetics (PK): Area under curve from time zero to time infinite(AUC0-inf)
Analysis of AUC0-inf
Time frame: 12 weeks
RGT001-075 pharmacokinetics (PK): Maximum observed concentration (Cmax)
Analysis of Cmax
Time frame: 12 weeks
RGT001-075 pharmacokinetics (PK): Time to achieve maximum concentration(Tmax)
Analysis of Tmax
Time frame: 12 weeks
RGT001-075 pharmacokinetics (PK): Elimination half-life(t1/2)
Analysis of t1/2
Time frame: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2024 to primary completion in Aug 2024, 5 months.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 5 months is below that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: RGT001-075
Regor Pharmaceuticals Inc.